Free Trial

Nyxoah Q4 2024 Earnings Report

Nyxoah logo
$10.51 +0.46 (+4.58%)
As of 03/14/2025 03:59 PM Eastern

Nyxoah EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.46
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.02 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Nyxoah Earnings Headlines

Nyxoah price target lowered to $15 from $16 at Stifel
Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
Nyxoah reports Q4 revenue EUR 1.3M
Nyxoah SA (NYXH) Q4 2024 Earnings Call Transcript
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

View Nyxoah Profile

More Earnings Resources from MarketBeat